CombiMatrix forms diagnostics subsidiary

May 10, 2005 — CombiMatrix Corp. has formed a wholly owned subsidiary, CombiMatrix Molecular Diagnostics Inc. to develop DNA microarrays for molecular diagnostics, Acacia Research Corp. announced today. Matthew C. Watson will serve as CombiMatrix Molecular Diagnostics’ chief executive officer and David A. Baunoch will be president and chief operating officer.

Both previously worked at US LABS. Watson was vice president of laboratory operations and Baunoch was vice president of research and development. Watson worked at Nichols Institute (now Quest Diagnostics) and Specialty Laboratories before joining US LABS. Baunoch was an assistant professor in pathology at the University of Chicago and director of new product development at Ventana Medical Systems before moving to US LABS.

Acacia Research Corp. oversees two operating groups: Acacia Technologies Group and CombiMatrix Group. Acacia Technologies develops, acquires, and licenses patented technologies. CombiMatrix develops a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix’s group’s technology has potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material and nanotechnology.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.